Kumaraguru Raja
Stock Analyst at Brookline Capital
(0.05)
# 4,356
Out of 4,964 analysts
16
Total ratings
14.29%
Success rate
-45.25%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kumaraguru Raja
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INTS Intensity Therapeutics | Upgrades: Buy | $3 | $0.30 | +893.71% | 1 | Aug 12, 2025 | |
| PALI Palisade Bio | Maintains: Buy | $16 | $0.66 | +2,311.45% | 2 | May 13, 2025 | |
| QNCX Quince Therapeutics | Initiates: Buy | $9 | $1.56 | +476.92% | 1 | Dec 18, 2024 | |
| SABS SAB Biotherapeutics | Initiates: Buy | $8 | $2.12 | +277.36% | 1 | Jun 7, 2024 | |
| FBRX Forte Biosciences | Initiates: Buy | $100 | $11.01 | +808.27% | 2 | May 30, 2024 | |
| OTLK Outlook Therapeutics | Downgrades: Hold | n/a | $2.38 | - | 1 | Aug 30, 2023 | |
| ADIL Adial Pharmaceuticals | Reiterates: Buy | $150 | $0.38 | +39,115.69% | 2 | Jul 11, 2023 | |
| GNTA Genenta Science | Assumes: Buy | $15 | $3.80 | +294.74% | 1 | Jun 29, 2023 | |
| RAIN Rain Enhancement Technologies Holdco | Reinstates: Buy | $21 | $3.48 | +503.45% | 1 | Jan 31, 2023 | |
| MNPR Monopar Therapeutics | Reinstates: Buy | $90 | $34.81 | +158.55% | 1 | Dec 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $290 → $310 | $3.29 | +9,322.49% | 2 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $33,600 | $5.29 | +635,060.68% | 1 | Sep 21, 2021 |
Intensity Therapeutics
Aug 12, 2025
Upgrades: Buy
Price Target: $3
Current: $0.30
Upside: +893.71%
Palisade Bio
May 13, 2025
Maintains: Buy
Price Target: $16
Current: $0.66
Upside: +2,311.45%
Quince Therapeutics
Dec 18, 2024
Initiates: Buy
Price Target: $9
Current: $1.56
Upside: +476.92%
SAB Biotherapeutics
Jun 7, 2024
Initiates: Buy
Price Target: $8
Current: $2.12
Upside: +277.36%
Forte Biosciences
May 30, 2024
Initiates: Buy
Price Target: $100
Current: $11.01
Upside: +808.27%
Outlook Therapeutics
Aug 30, 2023
Downgrades: Hold
Price Target: n/a
Current: $2.38
Upside: -
Adial Pharmaceuticals
Jul 11, 2023
Reiterates: Buy
Price Target: $150
Current: $0.38
Upside: +39,115.69%
Genenta Science
Jun 29, 2023
Assumes: Buy
Price Target: $15
Current: $3.80
Upside: +294.74%
Rain Enhancement Technologies Holdco
Jan 31, 2023
Reinstates: Buy
Price Target: $21
Current: $3.48
Upside: +503.45%
Monopar Therapeutics
Dec 9, 2022
Reinstates: Buy
Price Target: $90
Current: $34.81
Upside: +158.55%
May 18, 2022
Maintains: Buy
Price Target: $290 → $310
Current: $3.29
Upside: +9,322.49%
Sep 21, 2021
Initiates: Buy
Price Target: $33,600
Current: $5.29
Upside: +635,060.68%